MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism

FEBS Letters

Volumn 584, Issue 22, 2010, Pages 4695-4702

  Polański, Radosław ^a   Warburton, Hazel E ^a   Ray Sinha, Arpita ^a   Devling, Timothy ^a   Pakula, Hubert ^a   Rubbi, Carlos P ^a   Vlatković, Nikolina ^a   Boyd, Mark T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Invasion; MDM2; Motility; P53; RING finger; Ubiquitin ligase

Indexed keywords

PROTEIN MDM2; RING FINGER PROTEIN; UVOMORULIN;

ARTICLE; CANCER CELL; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVE SITE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIFE EXPECTANCY; MOLECULAR DYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION; UPREGULATION;

ANIMALS; BASE SEQUENCE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MDM2; RING FINGER DOMAINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78249240580     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.10.049     Document Type: Article

References (25)

1. Iwakuma T., Lozano G. MDM2, an introduction. Mol. Cancer Res. 2003, 1:993-1000.
2. Ganguli G., Wasylyk B. P53-independent functions of MDM2. Mol. Cancer Res. 2003, 1:1027-1035.
3. Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med. 1996, 2:912-917.
4. Lundgren K., et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev. 1997, 11:714-725.
5. Jones S.N., Hancock A.R., Vogel H., Donehower L.A., Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 1998, 95:15608-15612.
6. Kannemeier C., Liao R., Sun P. The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance. Mol. Biol. Cell 2007, 18:2367-2377.
7. Maguire M., Nield P.C., Devling T., Jenkins R.E., Park B.K., Polanski R., Vlatkovic N., Boyd M.T. MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res. 2008, 68:3232-3242.
8. Wang S.P., et al. P53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 2009, 11:694-704.
9. Yang J.Y., et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol. Cell. Biol. 2006, 26:7269-7282.
10. Noon A.P., Vlatkovic N., Polanski R., Maguire M., Shawki H., Parsons K., Boyd M.T. P53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?. Cancer 2010, 116:780-790.
11. Boyd M.T., Vlatkovic N., Haines D.S. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2. J. Biol. Chem. 2000, 275:31883-31890.
12. Brady M., Vlatkovic N., Boyd M.T. Regulation of p53 and MDM2 activity by MTBP. Mol. Cell. Biol. 2005, 25:545-553.
13. Martinez L.A., Naguibneva I., Lehrmann H., Vervisch A., Tchenio T., Lozano G., Harel-Bellan A. Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. USA 2002, 99:14849-14854.
14. Warburton H.E., Brady M., Vlatkovic N., Linehan W.M., Parsons K., Boyd M.T. P53 regulation and function in renal cell carcinoma. Cancer Res. 2005, 65:6498-6503.
15. Thompson C.C., et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007, 56:95-106.
16. Haitel A., Wiener H.G., Baethge U., Marberger M., Susani M. Mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res. 2000, 6:1840-1844.
17. Moch H., et al. p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol. Res. 1997, 25(Suppl. 1):S25-S30.
18. Lane B.R., Rini B.I., Novick A.C., Campbell S.C. Targeted molecular therapy for renal cell carcinoma. Urology 2007, 69:3-10.
19. Brown D.R., Thomas C.A., Deb S.P. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J. 1998, 17:2513-2525.
20. Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 2000, 275:8945-8951.
21. Honda R., Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000, 19:1473-1476.
22. Xirodimas D.P., Saville M.K., Bourdon J.C., Hay R.T., Lane D.P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004, 118:83-97.
23. Itahana K., et al. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 2007, 12:355-366.
24. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
25. Ding K., et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 2006, 49:3432-3435.